Lilly targets spectrum pharma

Quote

Anonymous

Guest
16,342 views Gene Marcial, Contributor
I have an insider's take on Wall Street

“Spectrum could be a very attractive acquisition target for the bigger pharmaceutical companies, such as Abbott Laboratories (ABT), Bristol-Myers Squibb, Eli Lilly (LLY), Merck (MRK), Pfizer (PFE) and Teva,” says one investment manager at a hedge fund specializing in biotech investing. As one of the few profitable biotechs around, Spectrum is an enticing target, he adds, having demonstrated its ability to produce drugs with potentially huge markets. Moreover, some drugs that are in the pipeline have the potential of enhancing and contributing to the company’s oncology revenue
 


















Anonymous said:
It is all about the pipeline and they have it and we don't, sorry to say . A big budget is no guarantee of success and we have no success to brag about so beware.
Click to expand...

The WSJ just loves us. Are they on the payroll?

In case you didn't notice, our Alzheimer drug is now a success.

LCC+WSJ = a very happy marriage.
 


















TE=Anonymous;4527405]and a dividend is coming[/QUOTE]


Nevada-based biotech Spectrum Pharmaceuticals (Nasdaq: SPPI ) announced today that the U.S. Patent and Trademark Office granted a five-year extension on patent protection for its drug Folotyn. The patent was originally set to expire on July 16, 2017. The drug's patent will now expire in 2022. Folotyn net sales were approximately $50 million in 2011.

Folotyn is used to treat patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). PTCL, a type of non-Hodgkin's lymphoma, rarely occurs in the U.S. but is more common in Asia, Africa, and the Caribbean.

Allos Therapeutics developed Folotyn after its initial discovery by Memorial Sloan-Kettering Cancer Center, SRI International, and Southern Research Institute. The drug received accelerated approval from the FDA in 2009. Spectrum added Folotyn to its product portfolio with its acquisition of Allos last month.

The patent extension was granted under provisions of the Hatch-Waxman Act of 1984, which was meant to encourage development of generic drugs but also provide the possibility of extended patent protection for companies developing new drugs.

Dr. Rajesh C. Shrotriya, chairman and CEO of Spectrum Pharmaceuticals, said the patent extension allows Spectrum to achieve substantial expected revenue growth while reaching out to more physicians and patients.
 






Anonymous said:
TE=Anonymous;4527405]and a dividend is coming
Click to expand...


Nevada-based biotech Spectrum Pharmaceuticals (Nasdaq: SPPI ) announced today that the U.S. Patent and Trademark Office granted a five-year extension on patent protection for its drug Folotyn. The patent was originally set to expire on July 16, 2017. The drug's patent will now expire in 2022. Folotyn net sales were approximately $50 million in 2011.

Folotyn is used to treat patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). PTCL, a type of non-Hodgkin's lymphoma, rarely occurs in the U.S. but is more common in Asia, Africa, and the Caribbean.

Allos Therapeutics developed Folotyn after its initial discovery by Memorial Sloan-Kettering Cancer Center, SRI International, and Southern Research Institute. The drug received accelerated approval from the FDA in 2009. Spectrum added Folotyn to its product portfolio with its acquisition of Allos last month.

The patent extension was granted under provisions of the Hatch-Waxman Act of 1984, which was meant to encourage development of generic drugs but also provide the possibility of extended patent protection for companies developing new drugs.

Dr. Rajesh C. Shrotriya, chairman and CEO of Spectrum Pharmaceuticals, said the patent extension allows Spectrum to achieve substantial expected revenue growth while reaching out to more physicians and patients.[/QUOTE]

$50 million!!!!!!!!!!! This could be the next Lilly Blockbuster.
 






Re: Allergan buyout of SPECTRUM PHARMA
Re: Allergan buyout
Quote:
Originally Posted by Anonymous
MORE GREAT NEWS JUST RELEASED

7:26AM Spectrum Pharma provides update on Belinostat Registrational Trial for the treatment of relapsed/refractory peripheral T-Cell lymphoma; final analysis of the Trial has not been made and 7 patients continue on treatment (SPPI) 12.51 : Co provided an update regarding anticipated milestones for the analysis of data and potential regulatory filing related to the pivotal, registrational BELIEF trial of belinostat, a novel histone deacetylase (HDAC) inhibitor. On Sep 21, 2012, Topotarget A/S, Spectrum's collaboration partner for the joint development of belinostat, reported preliminary clinical results for the BELIEF trial, which is evaluating the efficacy and safety of belinostat for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). Spectrum is continuing to collect and analyze the data from the trial, and database lock is expected to occur in Nov/Dec 2012, following which a definitive determination of the primary endpoint of overall response rate (ORR) will be calculated. "We are very pleased with the ongoing data collection and its analysis from the BELIEF trial and look forward to a required meeting with the FDA once a definitive ORR has been determined," stated Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. "Pending final data analysis and agreement with the FDA, we anticipate filing of an NDA application by mid-2013, and FDA decision is likely in 2014."
When will allergan move and the rumored $20 takeout now seems too low
 






Top Bottom
Back
Quote